Answers are grounded in this paper and cite their sources.
Otomycosis is a common external auditory canal infection, frequently caused by Aspergillus and Candida species. Diagnostic limitations and species-dependent antifungal susceptibility contribute to recurrence and treatment challenges. This study aimed to determine species distribution and antifungal susceptibility patterns of otomycosis isolates in southern Iran. A cross-sectional study enrolled 104 patients with confirmed otomycosis (November 2018–March 2019). Molecular identification was performed by β-tubulin sequencing (molds) and ITS region sequencing (yeasts). Antifungal susceptibility testing against fluconazole, posaconazole, miconazole, terbinafine, amphotericin B, and nystatin followed CLSI microdilution methods (M38-Ed3 and M27-Ed4). Among 104 patients, 55% were female, and nearly half were aged 40–60 years. Itching (81.7%), inflammation (80%), and otorrhea (74%) were predominant symptoms. Cultures yielded 102 mold and 16 yeast isolates. Microscopic observation identified the A. niger complex as the predominant agents, while sequencing confirmed A. tubingensis (36.3%) and A. niger (28.4%) as the main species causing otomycosis. C. albicans and C. parapsilosis were the most frequent yeasts. Posaconazole and amphotericin B showed potent activity against most Aspergillus isolates, and 12 of the 16 Candida isolates (75%) remained fluconazole-susceptible. Molecular techniques significantly improved the accuracy of species identification of otomycosis agents, revealing a high frequency of A. tubingensis in this study population. Posaconazole and amphotericin B showed strong in vitro activity, while fluconazole showed limited efficacy against molds. Overall, continuous molecular surveillance is essential to guide optimal antifungal therapy and prevent resistance.
No takes yet. Share an insight, caveat, or question.
Yazdanpanah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: